Rallybio (RLYB) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free RLYB Stock Alerts $1.62 -0.12 (-6.61%) (As of 02:21 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFibroGen, Inc. (FGEN)finance.yahoo.com - April 23 at 4:19 PMRallybio Co. (NASDAQ:RLYB) Given Average Recommendation of "Moderate Buy" by Brokeragesamericanbankingnews.com - April 22 at 2:14 AMRallybio (NASDAQ:RLYB) Rating Reiterated by JMP Securitiesamericanbankingnews.com - April 20 at 1:30 AMRallybio's (RLYB) "Market Outperform" Rating Reiterated at JMP Securitiesmarketbeat.com - April 18 at 2:21 PMBuy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT Treatmentmarkets.businessinsider.com - April 18 at 1:36 AMRallybio (RLYB) Price Target Decreased by 16.00% to 12.85msn.com - April 17 at 8:35 PMFNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meetingbusinesswire.com - April 17 at 4:01 PMQ1 2024 Earnings Estimate for Rallybio Co. (NASDAQ:RLYB) Issued By Wedbushamericanbankingnews.com - April 15 at 1:16 AMCozad New Venture Challenge Demo Day awards student start-ups with fundingfinance.yahoo.com - April 14 at 12:50 AMRallybio partners with Johnson & Johnson on FNAIT treatmentinvesting.com - April 12 at 12:47 AMRare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Highermsn.com - April 11 at 2:43 PMRallybio partners with J&J to advance therapies targeting rare fetal diseaseproactiveinvestors.com - April 11 at 11:32 AMRallybio (NASDAQ:RLYB) PT Lowered to $11.00marketbeat.com - April 11 at 10:33 AMRallybio shares gain on investment from J&J for rare fetal condition treatmentmsn.com - April 11 at 9:43 AMWhy Is Rallybio (RLYB) Stock Up 93% Today?investorplace.com - April 11 at 7:43 AMBuy Rating Affirmed for Rallybio on Back of JNJ Collaboration and FNAIT Program Progressmarkets.businessinsider.com - April 11 at 12:16 AMRallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)businesswire.com - April 10 at 4:01 PMRallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meetingfinance.yahoo.com - April 1 at 2:05 PMBuy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market Potentialmarkets.businessinsider.com - March 13 at 3:53 PMBuy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial Stabilitymarkets.businessinsider.com - March 12 at 11:17 PMRallybio: Q4 Earnings Insightsbenzinga.com - March 12 at 6:16 PMRallybio Reports Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - March 12 at 1:16 PMRallybio to Present at the TD Cowen 44th Annual Health Care Conferencebusinesswire.com - February 26 at 8:00 AMFY2023 Earnings Estimate for Rallybio Co. Issued By HC Wainwright (NASDAQ:RLYB)marketbeat.com - February 9 at 6:27 AMFY2028 Earnings Estimate for Rallybio Co. Issued By Wedbush (NASDAQ:RLYB)marketbeat.com - February 8 at 8:54 AMJefferies cuts Rallybio to hold, cites lack of near-term catalystsmsn.com - February 7 at 5:07 PMRallybio Announces Workforce Reduction and Restructuring Costsmsn.com - February 7 at 12:06 PMRallybio (NASDAQ:RLYB) Price Target Cut to $8.00marketbeat.com - February 7 at 11:35 AMRallybio’s Strategic Focus and Strengthened Fiscal Position Garner Buy Ratingmarkets.businessinsider.com - February 7 at 7:06 AMRallybio Announces Portfolio Prioritization Plan; To Reduce Workforce By 45%markets.businessinsider.com - February 6 at 3:31 PMMadrigal Pharmaceuticals, Cerus among healthcare moversmsn.com - February 6 at 10:30 AMRallybio to Cut 45% of Staff in Portfolio Prioritizationmarketwatch.com - February 6 at 10:30 AMRallybio shares jump 13% on restructuring, cash runway extensionmsn.com - February 6 at 10:30 AMRallybio Announces Portfolio Prioritization and Provides Corporate Updatefinance.yahoo.com - February 6 at 10:30 AMCanada's economy likely grew in December, avoiding recessionmsn.com - February 2 at 10:34 PMRallybio’s Drug Pipeline Promises Breakthroughs in FNAIT and gMG Treatments: Kapoor Maintains Buy Ratingmarkets.businessinsider.com - January 6 at 2:19 AMRallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024finance.yahoo.com - January 4 at 12:38 PMBuy Rating Affirmed for Rallybio on Strong Phase 1b Results and Strategic Focusmarkets.businessinsider.com - December 21 at 1:12 PMRallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5finance.yahoo.com - December 20 at 9:33 AMRallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65 th American Society of Hematology Annual Meetingbusinesswire.com - December 10 at 3:46 PMRallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meetingfinance.yahoo.com - December 9 at 12:39 PMBuy Rating Affirmed for Rallybio as RLYB212 Shows Promise in FNAIT Treatment Advancementsmarkets.businessinsider.com - November 29 at 5:21 AMRallybio posts early Phase 1 data for lead candidate in bleeding disordermsn.com - November 28 at 5:43 PMRallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopeniafinance.yahoo.com - November 28 at 7:43 AMRallybio Corp RLYBmorningstar.com - November 25 at 2:27 PMExpert Ratings for Rallybiomarkets.businessinsider.com - November 10 at 1:03 PMPromising Pipeline and Strong Financial Performance: Rallybio Earns ‘Buy’ Ratingmarkets.businessinsider.com - November 10 at 8:02 AMRallybio GAAP EPS of -$0.45msn.com - November 9 at 3:44 PMRallybio: Q3 Earnings Insightsbenzinga.com - November 9 at 10:44 AMRallybio Reports Third Quarter 2023 Financial Results and Provides Business Updatesfinance.yahoo.com - November 9 at 10:44 AM Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address $25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time… Go here to watch the most recent trading workshop video at no charge. RLYB Media Mentions By Week RLYB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLYB News Sentiment▼0.530.44▲Average Medical News Sentiment RLYB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLYB Articles This Week▼81▲RLYB Articles Average Week Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MediciNova News Viveon Health Acquisition News Landos Biopharma News Celularity News Anebulo Pharmaceuticals News Lantern Pharma News Eagle Pharmaceuticals News Mural Oncology News Journey Medical News Carisma Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLYB) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Goldtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
